Try to Avoid PPIs With New Hep C Med Epclusa

September 2016

Please see the October 2016 FDA advisory about the risk of Hepatitis B reactivation in some patients being treated for Hepatitis C.

Epclusa (ep-KLOO-suh, sofosbuvir/velpatasvir) will further simplify hepatitis C treatment.

So far, other recent hep C meds (Harvoni, Zepatier, etc) can only be used for certain hep C genotypes...and treatment duration varies.

But Epclusa is a one-tab, once-daily med that can be used for ANY hep C genotype...and patients use just a 12-week course.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

12 issues every year, with brief articles about new meds and guidelines
48+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

Heart Failure Remind Heart Failure Patients to Watch for Sodium in OTCs
Angina Choose a Long-Acting Nitrate for Angina Based on Ease of Use and Cost
Ophthalmology Switch to Preservative-Free Artificial Tears When Using Over Four Times Daily
HIV & AIDS Use Either Form of Tenofovir for Most HIV Patients
Opioids Expect Improvements to Your State's Rx Drug Monitoring Program
Constipation Don't Count On Docusate for Treating Constipation in Most Patients
Epinephrine Don't Jump to Epinephrine Vials if Cost Is an Issue With Auto-Injectors
Oral Health Use Doxycycline in Kids When Its Benefits Outweigh Risks of Teeth Staining
Use These Tools to Make Shared Decision Making More Effective
Women's Health Consider Estrogen-Containing Contraceptives in Women With Menstrual Migraine
Hepatitis C Try to Avoid PPIs With New Hep C Med Epclusa